EP Patent

EP1578341A2 — Modulation of ccr4 function

Assigned to Tularik Inc · Expires 2005-09-28 · 21y expired

What this patent protects

Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

USPTO Abstract

Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

Drugs covered by this patent

Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb

Patent Metadata

Patent number: EP1578341A2
Jurisdiction: EP
Classification: —
Expires: 2005-09-28
Drug substance claim: No
Drug product claim: No
Assignee: Tularik Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.